Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: An observational, prospective, controlled study by Bikalpa Neupane, Hitesh Pandya, Tej Pandya, Rupert Austin, Neil Spooner, James Rudge, Hussain Mulla

Get full text

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab by Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Dirk Garmann

Get full text

Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data by Stefan Willmann, Adam Lloyd, Rupert Austin, Shiju Joseph, Alexander Solms, Yang Zhang, Annika R. P. Schneider, Sebastian Frechen, Marcus‐Hillert Schultze‐Mosgau

Get full text

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer by Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H. Prins, John Lettieri, David Mitchell, Funan Huang, Marcia S. Brose, Martin Schlumberger, Gerold Meinhardt, Carol E. A. Peña, Bart A. Ploeger

Get full text